ARID1A and endometrial carcinoma: Endometrioid endometrial carcinoma, accounting for 49.0% of our study, was characterized by genomic alterations of PTEN (47.6% vs. 13.7%, p < 0.001), KRAS (30.9% vs. 17.8%, p = 0.0037), CTNNB1 (23.6% vs. 2.1%, p < 0.001), and ARID1A (37.8% vs. 22.6%, p = 0.0015), compared with non-endometrioid endometrial carcinomas (serous, clear cell, and mixed carcinomas) (Figure 2A).